Valneva (NASDAQ:VALN) Sees Strong Trading Volume – What’s Next?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) saw strong trading volume on Friday . 2,094,686 shares traded hands during trading, an increase of 3,213% from the previous session’s volume of 63,226 shares.The stock last traded at $7.1310 and had previously closed at $5.65.

Trending Headlines about Valneva

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s marketing authorization application for their six-valent Lyme disease vaccine candidate, PF-07307405. Validation begins the EMA’s formal review and represents an important regulatory milestone, although it is not an approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Management said Pfizer expects key Lyme vaccine decisions within roughly 12 months, giving investors a clearer timeline for a potentially significant future growth driver. The program is being developed with Pfizer, which could provide Valneva with milestone and commercial opportunities. Valneva outlines 2026 revenue guidance while Pfizer targets Lyme decisions
• Positive Sentiment: Valneva reaffirmed its 2026 revenue outlook of approximately €145 million to €160 million, indicating continued confidence in its commercial vaccine portfolio despite near-term losses. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
• Neutral Sentiment: TD Cowen initiated research coverage on Valneva. The coverage may improve institutional visibility, but the available report does not specify an investment rating or price target. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Second-quarter results missed expectations: Valneva reported a $0.40 per-share loss versus the $0.23 consensus loss, while revenue of $39.37 million came below the $43.15 million estimate. The company remains deeply unprofitable, increasing the importance of successful product sales and the Lyme vaccine program. Valneva quarterly earnings results

Analyst Ratings Changes

VALN has been the subject of a number of analyst reports. The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a research report on Wednesday, April 22nd. Guggenheim set a $11.00 target price on shares of Valneva in a research note on Thursday, April 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th. TD Cowen assumed coverage on shares of Valneva in a report on Tuesday. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Four analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.98.

Valneva Stock Up 23.9%

The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60. The company has a fifty day moving average price of $5.21 and a 200 day moving average price of $6.92. The company has a market cap of $664.23 million, a PE ratio of -3.74 and a beta of 1.77.

Valneva (NASDAQ:VALN) last announced its earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The company had revenue of $39.37 million during the quarter, compared to analysts’ expectations of $43.15 million. As a group, analysts anticipate that Valneva SE Sponsored ADR will post -1 EPS for the current year.

Institutional Trading of Valneva

Hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new position in Valneva in the fourth quarter worth $44,000. Marex Group plc bought a new position in Valneva in the second quarter valued at $64,000. XTX Topco Ltd purchased a new stake in Valneva during the fourth quarter valued at about $94,000. Finally, JPMorgan Chase & Co. purchased a new stake in Valneva during the third quarter valued at about $124,000. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.